Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
Janssen-Cilag Pty Ltd
This is a dose escalation and expansion study, in which patients will be assigned to receive either an escalating or recommended dose of intravenous JNJ-61186372. The starting dose of JNJ-61186372, which will be given to the first cohort of patients, will be 140mg. Each subsequent cohort will receive intravenous JNJ-61186372 at increased dose levels. Participants will receive intravenous infusion of JNJ-61186372 once weekly during cycle 1 and once every 2 weeks during subsequent cycles. The duration of each treatment cycle is 28 days.